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Recombinant human erythropoietin (rHuEPO) increases
endothelin-1 release by endothelial cells
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and MARCOS ROTHSTEIN
Renal Division, Jewish Hospital and Barnes Hospital at Washington University Medical School, St. Louis, Missouri, USA
Recombinant human erythropoietin (rHuEPO) increases endothelin-!
release by endothelial cells. Hypertension is a major complication of
rHuEPO therapy in hemodialysis (HD) patients. We have previously
reported that patients receiving rHuEPO intravenously (i.v.) had higher
mean arterial pressure (MAP) and plasma endothelin-l (ET-l) levels
than those in which the hormone was administered subcutaneously
(s.c.). To test whether the increased serum ET-l levels associated with
i.v. rHuEPO administration are the result of a direct effect of the
hormone on ET-l release by the endothelial cells (EC), we examined
the effects of rHuEPO in vitro. Bovine pulmonary artery endothelial
cells (BPAEC) were exposed to doses of rHuEPO of 0.8; 1.6; 3.3 and
6.6 U/mI. A 24 hour-time course showed maximal ET-l production at 12
hours for all the doses tested. A significant increase in cell proliferation
over controls was observed at 24 hours, for all rHuEPO doses, and no
correlation was found between ET-l values and cell proliferation.
Inhibition of protein synthesis by cycloheximide (10 sgIml) abolished
the stimulation of ET-l release by rHuEPO. Thrombin (4 U/ml) and
angiotensin II (l0 54), two potent stimulators of ET-l release, had
additive effects to those of rHuEPO. Specific thrombin and angiotensin
II antagonists blocked these additive effects, reducing ET-1 release to
the level of rHuEPO stimulation alone. In summary, rHuEPO stimu-
lates vascular EC in culture to increase ET-l release through an
increase in synthesis and in a time dependent fashion. The routes of
stimulation seem to differ from other known FT-I secretogoges. Our
data also confirm a significant mitogenic effect of rHuEPO on the
endothelial cell.
Within three years of its introduction in clinical medicine,
recombinant human erythropoietin (rHuEPO) has gained wide
acceptance for the treatment of the anemia of chronic renal
failure [1, 2]. Application of this hormone to other anemias
unrelated to renal disease is being actively pursued [3—5].
Hypertension is the major complication of rHuEPO therapy
arising in at least a third of the hemodialysis (HD) population
treated with the hormone [1, 2, 6, 7]. Other complications such
as vascular thrombotic events have also been observed [8].
Mechanisms proposed to explain the pathogenesis of rHuEPO-
induced hypertension are based on an increase in peripheral
vascular resistance. They include increases in blood viscosity
[9, 10], increments in cytosolic calcium in vascular smooth
muscle and platelets [11, 12], and a direct pressor effect [131.
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However, none of these proposed mechanisms have been
conclusively demonstrated.
Endothelin (ET-l), a naturally occurring vasoconstrictive
peptide, has been purified from vascular endothelial cells (EC)
in culture [14, 15]. In animal models, ET-l infusion results in
sustained elevations in the mean arterial pressure (MAP) [16,
17]. We have previously demonstrated that plasma ET-l levels
were higher in HD patients treated with rHuEPO intravenously
(i.v.) than in patients treated with rHuEPO subcutaneously
(s.c.) [18]. Only the patients treated with i.v. rHuEPO had a
significant correlation between ET-1 plasma levels and MAP.
We conclude that the administration route may be critical in the
rHuEPO-associated hypertension.
The identification of a 45 kDa erythropoietin (EPO) receptor
[19] in human umbilical endothelial cell line (HUVEC) suggests
that EPO interacts with other cell types in addition to erythroid
progenitor cells [20—22]. The vascular endothelium may be
another target for the action of the hormone. In order to clarify
whether serum ET- 1 levels depend on the rHuEPO administra-
tion route and whether rHuEPO had direct actions on ET-1
release by EC, we examined ET-1 release from bovine pulmo-
nary artery endothelial cells (BPAEC) stimulated by rHuEPO.
Methods
Endothelial cell culture
BPAEC from American Type Tissue Culture Collection
(ATCC, CCL-209, Rockville, Maryland, USA) were grown in
Minimum Essential Media Eagle (MEM; Sigma Chemical Co.,
St. Louis, Missouri, USA) supplemented with 20% fetal bovine
serum, antibiotic free. The cells were incubated at 37°C in a
humidified 5% C02: 95% air atmosphere. The cells were pas-
saged weekly at a split ratio of 1:3 using the trypsin/EDTA
method. Confluent, monolayer cultures between the 18th to
24th passage were used. The cells were plated into 6 well
clusters (Costar Corp., Cambridge, Massachusetts, USA) at a
density of 3 x ion. The media were changed twice per week. On
day five, 24 hours prior to the experiment, when over 80% cell
confluency was achieved, the media were removed and 3 ml of
serum-free media (SFM) were added to each well.
Experimental groups
The SFM was removed and the cells were washed twice with
phosphate buffer saline (PBS) (pH 7.4), and reincubated (37°C)
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Doses
Endothelin-1 pg/pg DNA
1 hr 4 hr 12 hr 24 hr
Control 2.4 0.7 2.8 0.6 17.7 2.2 19.0 2.3
0.8 U/mi 2,9 0.2 9.2 0.5° 47.3 0.4a 36.4 1,4b
1.6 U/mi 2.9 0,4 24.6 3,5b 51.9 12.6° 52.2
3.3 U/mi 2.5 0.1 18.9 0.6c 58.4 86b 39.0 1.9"
6.6 U/mi 7.4 1.9° i9.3 1.IC 45.2 2.0° 37.8 07b
BPAEC were incubated in serum-free media (MEM) with 0.8; 1.6; 3.3
and 6.6 U/mi rHuEPO for 1; 4; i2 and 24 hours. Controi cells were
exposed to rHuEPO vehicle aione. ET-1 leveis are expressed as pg of
ET-1/sg of DNA. Results represent mean SD of three experiments
performed in duplicate. Each ET- 1 level was compared with its respec-
tive time point control.
a P < 0.05
b P < 0.001
P < 0.01
with 3 ml SFM and the various reagents detailed below. For
time-course experiments, the cells were exposed to rHuEPO
concentrations of 0.8, 1.6, 3.3, and 6.6 U/mi Epoetin Alfa
(Amgen, Inc., Thousand Oaks, California, USA) for one, four,
12, and 24 hours.
In the other experiments, cells were exposed for four hours to
a rHuEPO dose of 3.3 U/mI and to the following reagents (from
Sigma Chemical Co.): cycloheximide: 10 gIml; thrombin (Hu-
man): 4 U/mi; recombinant hirudin: 0.1 /m1; angiotensin II:
10 and [Sar' A1a8]-Ang II: 10—6 M. Control wells were
incubated with rHuEPO vehicle alone.
Endothelin RIA
After incubation, the media were aspirated and centrifuged at
2000 rpm for 10 minutes. Supernatant was then stored at —70°C.
ET-l was extracted using Sep-Pak C,8 cartridges (Water As-
soc., Milford, Massachusetts, USA) and ET-l determinations
were performed utilizing the ET- 1 radioimmunoassay (RIA) kit
(Peninsula Lab, Inc., Belmont, California, USA). The recovery
capability of the assay is 85% with a 100% specificity for ET- 1.
DNA assay
Wells were washed twice with 2 ml acetonitrile-water (1:1),
and the cells were then scraped and pooled. Samples were
vortexed for 30 seconds and centrifuged at 1500 g for 15
minutes. Total DNA in each well was assayed in the pellet using
the ethidium bromide method [23]. ET-l levels were corrected
for the DNA content of the well.
Statistics
Values are expressed as the mean standard deviation.
Analysis of variance (ANOVA) by Instat (GraphPAD Software,
Inc., USA) was used to compare differences between experi-
mental groups.
Results
Effects of rHuEPO on ET-1 release
Table 1 depicts ET- 1 release by BPAEC during a 24 hour
period of treatment with varying rHuEPO concentrations from
0.0 to 6.6 U/mI. A time-dependent increase in ET-l production
was observed in control and treated cells. Maximal levels of
Fig. 1. Percent increase of ET-1 levels over control. BPAEC were
incubated in serum-free media (MEM) for 1; 4; 12 and 24 hours with 0.8(—); 1.6 (.— -. ); 3.3 (——--—); and 6.6 ( ) U/mi rHuEPO,
respectively.
ET-1 release were observed at 12 hours in all the conditions
tested.
Figure 1 depicts the percent increase of ET-1 release over
control levels. At all doses, maximal rHuEPO stimulation was
observed at four hours. At the highest dose of 6.6 U/mi, there
was a 210% increase in one hour. After 24 hours exposure, the
increase in ET-l levels above control (86 to 167%) was not
statistically significant for the different doses except for the 1.6
U/well (P < 0.01).
To assess whether ET-1 stimulation by rHuEPO is produced
through new protein synthesis, we tested the effect of cyclo-
hexamide, a protein synthesis inhibitor. As demonstrated in
Figure 2, incubation of EC with 3.3 U/mi rHuEPO and 10 g/m1
cycloheximide (a dose which blocked 3H-leucine incorporation)
failed to stimulate ET-1 release above control values. This
demonstrated that the stimulation of ET-1 release by rHuEPO
was dependent on new protein synthesis.
To further identify the mechanisms by which rHuEPO stim-
ulates ET-1 secretion, we studied the effects of angiotensin II
and thrombin. A dose-response for the effect of angiotensin II
(from i05 to 10—8 M) on ET-1 release showed maximal
stimulation at the lO M dose (data not shown). After a four
hour incubation, both angiotensin II (1O M) and rHuEPO (3.3
U/mi) significantly stimulated ET-1 release over controls (Fig.
3). Simultaneous incubation of rHuEPO with angiotensin II
revealed an additive effect. When the angiotensin II receptor
antagonist [Sar'-A1a8]-Ang II was introduced, it completely
abolished the effects of angiotensin II without alterations in the
rHuEPO-promoted ET-1 secretion. Using a similar experimen-
tal design, thrombin was utilized as a co-stimulator of ET-1
release by rHuEPO. Increasing thrombin concentrations from 3
U/mi to 5 U/mI revealed maximal ET-l stimulation at 4 U/mi.
Figure 4 demonstrates an additive thrombin effect on rHuEPO
stimulation which was blocked by hirudin, a specific thrombin
inhibitor, which does not affect the response to rHuEPO.
Effects of rHuEPO on cell proliferation
rHuEPO effects on ET-l release could have been mediated
by an increase in cell number. Thus DNA levels in the 6-well
Table 1. Time course and dose response for the effect of rHuEPO on
ET-l production
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Fig. 2. Effect of cycloheximide on rHuEPO stimulation of ET-J re-
lease. BPAEC were incubated in serum-free media (MEM) for 4 hours
with rHuEPO vehicle control (U); 3.3 U/mI rHuEPO (); 3.3 U/mI
rHuEPO and 10 g/ml cycloheximide (11101). Bar and error bars
represent the mean SD of three experiments performed in duplicate.
*D < 0.01 control vs. rHuEPO; **p < 0.001 rHuEPO vs. rHuEPO +
cycloheximide.
Fig. 3. Effect of angiotensin II and [Sar1-A1a8J-ANG II on rHuEPO
stimulation of ET-1 release. BPAEC were incubated in serum-free
media (MEM) for 4 hours with rHuEPO vehicle control (U); 3.3 U/mI
rHuEPO (); lO M angiotensin II (); 3.3 U/ml rHuEPO + iO
M angiotensin II (); 3.3 U/mI rHuEPO + l0— M angiotensin II +
106 M [Sar'-A1a8]-ANG II ( lull). Bar and error bars represent mean
SD of three experiments performed in duplicate. < 0.05 control vs.
rHuEPO; **D < 0.001 rHuEPO vs. rHuEPO + angiotensin II; *** <
0.01 control vs rHuEPO + angiotensin II + [Sar'-Ala9-Ang II.
cluster plates were measured. We observed that after 12 hours,
rHuEPO began to increase the BPAEC number at 6.6 U/mi
(data not shown). After 24 hours exposure, all rHuEPO doses
stimulated cell proliferation 35 to 60% above controls (Fig. 5)
with the highest dose, 6.6 U/mI, exerting a significant prolifer-
Fig. 4. Effect of thrombin and hirudin on rHuEPO stimulation of ET-1
release. BPAEC were incubated in serum-free media (MEM) for 4
hours with rHuEPO vehicle control (U); 3.3 U/mI rHuEPO (); 4
U/mi thrombin (); 3.3 U/mI rHuEPO + 4 U/nil thrombin (); 3.3
U/mI rHuEPO + 4 U/mI thrombin + 0.1 g/ml hirudin (11110). Bar and
error bars represent the mean SD of three experiments performed in
duplicate. < 0.01 control vs. rHuEPO; < 0.01 rHuEPO vs.
rHuEPO + thrombin; < 0.01 control vs. rHuEPO + thrombin ÷
hirudin.
Fig. 5. Effect of rHuEPO on cell pro1feration. BPAEC were incubated
in serum-free media (MEM) for 24 hours with 0.8 (U); 1.6 (); 3.3()and6.6 ( ) U/miof rHuEPO. DNA is expressed as % increase
over controls. Bar and error bars represent the mean SD of three
experiments performed in duplicate.
ative stimulus by 12 hours (not shown). There was no correla-
tion between ET-1 and DNA levels.
Discussion
This study demonstrates the rHuEPO effect on ET-l release
by BPAEC. We found that rHuEPO has a direct stimulatory
effect on ET-1 release which was time-dependent. Stimulation
of ET-i release by rHuEPO reached a plateau at 12 hours. This
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could be due to a decrease in cell receptors as a result of cell
confluency. A decrease in receptor binding with increments in
cell density has been described for several other growth factors
[24]. The inhibitory effect of cycloheximide on ET- 1 release in
response to rHuEPO suggests that the hormone stimulates de
nova ET-l synthesis. We have confirmed the known effects of
angiotensin II and thrombin-stimulated ET-l release by BPAEC
[25—27], and also demonstrated that both compounds have a
synergistic effect with rHuEPO on ET-l release. rHuEPO
co-incubation with specific inhibitors or antagonists of both
compounds did not interfere with rHuEPO effects. This makes
it unlikely that stimulation of ET-l release by rHuEPO is
mediated by either angiotensin Ii or thrombin.
The ability of rHuEPO to increase ET- I release beyond the
maximal effect of the two potent slimulants, angioten sin II and
thrombin, suggests that the hormone promotes ET-I release
through a different pathway. Preliminary studies in our labora-
tory seem to indicate the calcium dependency of rHuEPO
stimulation on ET-l release (data not shown).
It is well known that rHuEPO interacts with its target cells
through specific surface receptors. Until recently, it was
thought that their expression was limited to erythroid precur-
sors {20.-22]. Anagnostou et al [19] have described a novel
rHuEPO receptor on HUVEC with a molecular weight different
from the ones expressed in cells in which this hormone exerts a
differentiationlmaturation effect. They also reported a dose-
dependent increase in cell proliferation after a seven day
incubation, demonstrating for the first time the mitogenic effect
of rHuEPO on non-hematopoietic cells. In our short-term
incubation studies (24 hours), we have also observed an average
50% increase in cell proliferation over controls, although dose-
dependency was not seen over that time period. It remains to be
clarified whether the mitogenic rHuEPO effects on BPAEC are
a direct action of the hormone, as seen in the erythroid
progenitors, or are mediated by the release of FT-I acting in an
autocrine fashion. It is possible that both rHuEPO and ET-l act
synergistically promoting mitogenesis.
The possible chronic FT-i effects in vascular remodeling and
regulation of cell proliferation have yet to be explored. FT-I is
a powerful mitogen for cultured vascular smooth muscle cell
[28] and glomerular mesangial cells [29]. Its effects are mediated
through an increase of the protooncogenes, c-fos and c-inyc
mRNA levels [30]. Indeed, chronically enhanced local produc-
tion by the macro- and microvascular endothelium may lead to
vascular smooth muscle hyperplasia and hypertrophy, poten-
tially leading to the acceleration of atherosclerosis. Clinical
studies that correlate atherosclerotic sites and ET-l levels are
suggestive of this hypothesis [31].
Hypertension and hypercoagulability have been recognized
as complications of rHuEPO therapy in HO patients [1, 2, 6—8J.
Until now, no single cause-effect relationship has been found to
explain this problem. Although the pathophysiological role of
endothelin remains unclear, high FT-I levels have been de-
scribed in essential hypertension [32]. Uremia has also been
found to increase ET-l levels [33—36].
Earlier we had also shown that HO patients receiving i.v.
rHuEPO had a significant correlation between ET-l plasma
levels and MAP [18]. rHuEPO i.v. administration results in
very high serum levels of the hormone [37, 38], exposing the
vascular endothelium to supraphysiological rHuEPO concen-
trations. Such high rHuEPO plasma levels could induce ET-l
release by EC.
In summary, the present work provides an in vitro explana-
tion for the vascular and hypertensive effects of pharmacolog-
ical rHuEPO administration.
Acknowledgments
This work was supported in part by grants from NIH: DK-09976,
DK-30l78 and DK-07126. The authors thank Randall Duncan, Ph.D.,
for technical assistance and Debbie Windle for secretarial assistance.
Reprint requests to Marcos Rothstein, M.D., Jewish Hospital, Renal
Division, 216 5. Kingshi.ghway, St. Louis, Missouri 63178, USA.
References
1. EscunAcH SW, ABDULHAD1 MH, BROwNE 5K, DELANO BG,
DOWNING ME, FORTE IC, EVANS RW, FRIEDMAN FA, GRADER
SE, HALEY NR, KORBET 5, K1LANTz SB, LUNDIN AP, NssssNsoN
AR, OGDEN DA, PAGAN1NI EP, RADaR B, RUTSKY EA, STIvEL-
MAN I, STONE WI, TEScHAN P, VAN STONE IC, VAN WYCK DB,
ZUcKERMAN K, ADAM5ON SW: Recombinant human erythropoie-
tin in anemic patients with end-stage renal disease: Results of a
phase tIl multicentre clinical trial. Ann Intern Med 111:992—1000,
1989
2. AKIZAWA T, Kossmc.kwA 5, TAKAKU F, URABE A, AKIYAMA N,
MIMUItp. N, OTsuno 0, NIHEI H, SUZUKI Y, KAWAGUcHI Y, OTA
K, Kuno K, MARUMO F, MAEDA T: Clinical effect of recombinant
human erythropoietin on anemia associated with chronic renal
failure. A multi-institutional study in Japan. In: J Ar:if Organs
11:343—350, 1988
3. LUDWiG H, FRITZ E, KOTZMANN U, HOcKER P, GISSLINGER H,
BARNAS U: Erythropoietin treatment of anemia associated with
multiple myeloma. N Engi J Med 322:1693—1699, 1990
4. Pir'wus T, OLSEN NJ, RUSSELL LI, WOLFE F, HARRIS ER,
ScIINITZER TI, BoccAnNo IA, KRANTZ SB: Multicenter study of
recombinant human erythropoietin in correction of anemia in
rheumatoid arthritis. Am J Med 89:161—168, 1990
5. FISCHL M, GALPTN SE, LEVINE JD, GROOPMAN JE, HENRY DH,
KENNEDY P, MILES 5, ROBaINs W, STARRETT B, ZALUSKY R,
ABELS RI, TSAI HC, RUDNICK SA: Recombinant human erythro-
poietin for patients with AIDS treated With zidovudine. N Engi 3
Med 322:1488—1493, 1990
6. SAMTLEBEN W, BALDAMU5 CA, BOMMER J, FA55BINDER W,
NONNA5T-DANIEL B, GURLAND HJ: Blood pressure changes dur-
ing treatment with recombinant human erythropnietin. Contrib
Nephrol 66:114—122, 1988
7. SUNDAL F, KAESER U: Correction of anaemia of chronic renal
failure with recombinant human erythropoietin: Safety and efficacy
of one year's treatment in a European multicentre study of 150
hemodialysis-dependent patients. Nephroi Dial Transplant 4:979-
987, 1989
8. FAULDS D, SomclN EM: Epoetin (recombinant human erythropoi-
etin): A review of its pharmacoidnetic properties and therapeutic
potential in anemia and the stimulation of erythrupoiesis, Drugs
38:863—899, 1989
9. SCHAEFER EM, LEScNTCE M, STRAUER BE, HEIDLAND A: Blood
rheology and hypertension in hemodialysis patients treated with
erythropoietin. Am .1 Nephrol 8:449—453, 1988
10. LEsscHE D, SCHMIDT R, ZOELLNER K, MaSER W, PAULITSCI-IKE M,
DI5TLER B, KLINKMANN H: Rheology in whole blood and in red
blood cells under recombinant human erythropoietin therapy. Con-
trib Nephrol 76:299—305, 1989
11. JAMGOTCHIAN N, KEALL IF, HUMS, ADnELLAP, LEE DBN: An
animal model for recombinant human erythropoietin (rHuEPO)-
induced hypertension. (abstract) Kidney In: 37:387, 1990
12. VAN GEET C, VAN DAMME-LOMBAERTS R, VANRUSSELT M, DE-
MOL A, PROESMAN5 W, VERMYLEN J: Recombinant human eryth-
ropojetin increases blood pressure, platelet aggregability and plate-
let free calcium mobilisation in uraemic children: A possible link?
Thromb Jilae,nost 64:7—10. 1990
1014 Carliniet al: rHuEPO increases ET-l release by BPAEC
13. HEIDENRLIcH S, RAHN KH, ZrnEK W: Direct vasopressor effect of
recombinant human erythropoietin on renal resistance vessels.
Nephrol Dial Transplant 5:739—740, 1990
14. YANAGISAWA M, KURIHARA H, KIMuI S, TOMOBE Y, KOBA-
YASHI M, MITSUI Y, YA.zAIU Y, GoTo K, MASAKI T: A novel
potent constrictor peptide produced by vascular endothelial cells.
Nature (Lond) 332:411—415, 1988
15. XUAN Y-T, WHORTON AR, SHEARER-POOR E, BOYD J, WATKINS
WD: Determination of immunoreactive endothelin in medium from
cultured endotheial cells and human plasma. Biochem Biophys Res
Commun 164:326—332, 1989
16. HAN SP, TRAPANI AJ, FOK KF, WESTFALL TC, KNUEPFER MM:
Effects of endothein on regional hemodynamics in conscious rats.
Eur J Pharmacol 159:303—305, 1989
17. OUCH! Y, SEUNGBUM K, SOUZA AC, IUIMA S, HATFORI A, ORIM0
H, YosHizuMi M, KURIHARA H, YAZAKI Y: Central effect of
endothelin on blood pressure of conscious rats. Am J Physiol
256:H1747—H1751, 1989
18. CA&uNI R, OBIAL0 C, ROTHSTEIN M: Intravenous erythropoietin
(rHuEPO) administration increases plasma endothelin and blood
pressure in hemodialysis patients. AJH 6:103—107, 1993
19. ANAGNOSTOU A, LEE ES, KESSIMIAN N, LEvIN50N R, STEINER
M: Erythropoietin has a mitogenic and positive chemotactic effect
on endothelial cells. Proc Natl Acad Sci USA 87:5978—5982, 1990
20. METCALF D: Peptide regulatory factors. Haemopoietic growth
factors 1. Lancet i:825—827, 1989
21. SAWYER ST, KRANTZ SB, GOLDWASSER E: Binding and receptor-
mediated endocytosis of erythropoietin in friend virus-infected
erythroid cells. J Biol Chem 262:5554-5562, 1987
22. D'ANDREA D, L0DISH HF, WONG GG: Expression cloning of the
murine erythropoietin receptor. Cell 57:277—285, 1989
23. LE PECQ JB, PAOLETFI C: A new fluorometric method for RNA and
DNA determination. Anal Biochem 17:100—107, 1966
24. VEOMEET G, KUSZYNSKI C, KAZAKOFF P, Rzzio A: Cell density
regulates the number of cell surface receptors for fibroblast growth
factor. Biochem Biophys Res Commun 159:694—709, 1989
25. EMORI T, HIRATA Y, OHTA K, SHICHIRI M, MARUMO F: Secretory
mechanism of immunoreactive endothelin in cultured bovine endo-
thelial cells. Biochem Biophys Res Commun 160:93—100, 1989
26. SCHINI YB, HENDRICKSON H, HEUBLEIN DM, BURNETT JC JR,
VANHOUTTE PM: Thrombin enhances the release of endothein
from cultured porcine aortic endothelial cells. Eur J Pharmacol
165:333—334, 1989
27. BOULANGER C, LUSCHER TF: Release of endothelin from the
porcine aorta: Inhibition by endothelium-derived nitric oxide. J
Gun Invest 85:587—590, 1990
28. HIRATA Y, TAKAGI Y, FUKUDA Y, MARUMO F: Endothelin is a
potent mitogen for rat vascular smooth muscle cells. Atherosclero-
sis 78:225—228, 1989
29. SIM0N50N MS, WANN 5, MENE P, DIJBYAK GR, KESTER M,
NAKAZATO Y, SEDOR JR, DUNN MJ: Endothelin stimulates phos-
pholipase C, Na/H exchange, c-fosexpression, and mitogenesis
in rat mesangial cells. J Clin Invest 83:708—712, 1989
30. KOMURO I, KURIHARA H, SUGIYAMA T, TAKAKU F, YAZAKI Y:
Endothelin stimulates c-fos and c-myc expression and proliferation
of vascular smooth muscle cells. FEBS Lett 238:249—252, 1988
31. LERMAN A, EDWARDS BS, HALLETT JEW, HEUBLEIN DM, SAND-
BERG SM, BURNETr JC JR: Circulating and tissue endothein
immunoreactivity in advanced atherosclerosis. New Eng J Med
325:997—1001, 1991
32. SAITO Y, NAKAO K, MUKOYAMA M, IMURA H: Increased plasma
endothelin level in patients with essential hypertension. N Eng J
Med 322:205, 1990
33. SHICHIBI M, HIRATA Y, ANDO K, EMORI T, OHTA K, KIM0T0 5,
OGURA M, IN0UE A, MARUMO F: Plasma endothelin levels in
hypertension and chronic renal failure. Hypertension 15:493—496,
1990
34. TOTSUNE K, MOURI T, TAKAHASHI K, OHNEDA M, SONE M,
SAITO T, YOSHINAGA K: Detection of immunoreactjve endothelin
in plasma of hemodialysis patients. FEBS Lett 249:239—242, 1989
35. WARRENS AN, CAssrnY MJD, TAKAHASHI K, GHATEIMA, BLOOM
SR: Endothelin in renal failure. Nephrol Dial Transplant 5:418—422,
1990
36. NEUMAYER HH, BROCKMOLLER J, FRITSCHKA E, ROOTS I, Sci-
GALLA P, WATFENBERG M: Pharmacokinetics of recombinant
human erythropoietin after s.c. administration and in long-term i.v.
treatment in patients on maintenance hemodialysis. Contrib Neph-
rol76:131—142, 1989
37. MCMAHON FG, VARGAS R, RYAN M, JAIN AK, ABELS RI, PERRY
B, SMITH IL: Pharmacokinetics and effects of recombinant human
erythropoietin after intravenous and subcutaneous injections in
healthy volunteers. Blood 76:1718—1722, 1990
